Exact Sciences may have had disappointing Q3 earnings, but its liquidity cushions and new product approval indicate strong ...

Highlights include delivering test results to 1.2 million patients including a record number with Cologuard and Etty DX. Growing total revenue 13% year over year while holding operating expenses flat, ...

A recent study, again, in the Annals of Internal Medicine showed how useful FIT testing is. You don’t need a bowel prep, you ...

Exact Sciences' Q3 report led to a ~25% drop in share price, due to a slight guidance cut and narrow revenue miss. Learn more ...

Exact Sciences shares plunged Wednesday after the maker of Cologuard reported widening losses and cut its outlook.

There's a new blood test to screen for colorectal cancer, but a new study found it's not as effective as a colonoscopy or ...

Cologuard is an at-home colon cancer screening kit that detects changes in genetic material indicating potential cancer or polyps. Medicare covers one kit per year under Original Medicare (Parts A and ...

Exact Sciences Corp (EXAS) reports a 13% revenue increase and record free cash flow, while navigating disruptions and ...

Exact Sciences has a multipronged approach to cancer testing. Current products are Cologuard, its flagship stool-based screening test for colorectal cancer, or CRC, and Oncotype DX, its tissue-based ...

The biomedical giant best known for its Cologuard at-home colon cancer screening test reported a loss of $38.2 million, or $0.21 per share, on revenue of $708.7 million.